OpenAI quietly posted the unreleased life science model gpt-rosalind-discovery, asking drug companies to become "tool dealers" OpenAI's API price page has recently added a name that should not appear

OpenAI quietly posted the unreleased life science model gpt-rosalind-discovery, asking pharmaceutical companies to become "tool dealers". On the API price page of OpenAI, a name that should not appear has recently appeared. A new model in the field of life sciences, gpt-rosalind-discovery, which has not yet been officially released, has quietly appeared. Its pricing is exactly the same as that of its already-disclosed counterpart gpt-rosalind-research. Based on this, the outside world speculates that this new model is aimed at the drug discovery process. This is not an isolated listing. OpenAI has established a separate brand called Rosalind for life sciences and has laid out multiple product delivery paths - it has previously teamed up with a number of pharmaceutical companies to explore AI drug research and development, and also launched a biodefense plan. What is even more noteworthy is the identity: Among the large head model manufacturers, OpenAI is the first company to set up an independent brand, independent access review and iterative model specifically for the field of life sciences. It positions itself very restrainedly, and only acts as a tool supplier - selling special models to approved institutions, but does not touch the drug pipeline itself, and will never plant seedlings in the fields of pharmaceutical companies. Life science is a land that is very attractive to large model manufacturers: it has strong payment capabilities and clear pain points. It is a typical high value-added vertical scenario. OpenAI’s current strategy is to first attract leading pharmaceutical companies and scientific research institutions at low prices, and accumulate data and methods in real scenarios. However, the reality is also facing us: the entire AI4Bio field still lacks the support of large-scale clinical verification, and the role of models is mostly limited to reducing manual labor for people, far from being able to independently decide the fate of new drugs. OpenAI is trying to break down the models according to tasks in the life sciences, and use this precise method to realize the investment as soon as possible. But the embarrassment right now is that it has not been made clear what the difference between these two models of the same price is, and how much real gains the new model can bring. Whether it can really gain a foothold in laboratories and pharmaceutical factories in the future will still have to wait for evaluation and experimental evidence to come out. via AI News (author: AI Base)